Microdomains in the cardiovascular system PDF
Preview Microdomains in the cardiovascular system
Cardiac and Vascular Biology Editor-in-chief: Markus Hecker Viacheslav Nikolaev Manuela Zaccolo Editors Microdomains in the Cardiovascular System Cardiac and Vascular Biology Editor-in-chief Markus Hecker Inst. of Physiology & Pathophysiology, Heidelberg University, Heidelberg, Germany Series Editor Johannes Backs Department of Cardiology, Heidelberg University, Heidelberg, Germany Marc Freichel Institute of Pharmacology, Heidelberg University, Heidelberg, Germany Thomas Korff Inst. of Physiology & Pathophysiology, Heidelberg University, Heidelberg, Germany Dierk Thomas Department of Internal Medicine III, Heidelberg University Hospital, Heidelberg, Germany The book series gives an overview on all aspects of state-of-the-art research on the cardiovascular system in health and disease. Basic research aspects of medically relevant topics are covered and the latest advances and methods covering diverse disciplines as epigenetics, genetics, mechanobiology, platelet research or stem cell biology are featured. The book series is intended for researchers, experts and graduates, both basic and clinically oriented, that look for a carefully selected collection of high quality review articles on their respective field of expertise. More information about this series at http://www.springer.com/series/13128 Viacheslav Nikolaev • Manuela Zaccolo Editors Microdomains in the Cardiovascular System Editors Viacheslav Nikolaev Manuela Zaccolo Institute of Experimental Cardiovascular Department of Physiology, Research Anatomy and Genetics University Medical Center University of Oxford Hamburg-Eppendorf Oxford Germany United Kingdom ISSN 2509-7830 ISSN 2509-7849 (electronic) Cardiac and Vascular Biology ISBN 978-3-319-54578-3 ISBN 978-3-319-54579-0 (eBook) DOI 10.1007/978-3-319-54579-0 Library of Congress Control Number: 2017952370 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland Preface Cardiovascular disease is the leading cause of death in the western world with an enormous global health care burden. Heart failure affects around 26 million indi- viduals worldwide costing dozens of billion dollar in the USA or Europe every year. Despite intensive medication, the 5-year survival for heart failure patients remains at only ~50%, and projections indicate a 46% prevalence increase from 2012 to 2030. Available therapeutic strategies are based on general blockade of neuro- hormonal mechanisms using β-blockers and inhibitors of the renin-angiotensin- aldosterone system. In addition, inhibitors or natriuretic peptide degradation was recently introduced into the medical practice, while designer natriuretic peptides are in clinical trials. However, treatment remains symptomatic and results are unsatis- factory for a significant number of patients: current drugs associate with serious side effects and are ineffective for some patient groups. Present therapeutic strategies largely ignore signalling processes occurring in cardiomyocytes at the subcellular level. Evidence accumulating over the past few decades clearly shows that cardiac dis- ease is associated with dramatic alterations in functionally relevant subcellular microdomains where the major second messengers cAMP, cGMP and calcium come into action. To understand how such microdomains work and regulate cardiac function and disease, several new technologies, including biosensors for live cell imaging as well as sophisticated biochemical, electrophysiological and non-optical imaging techniques, have been developed and widely applied to cardiac and vascu- lar cells. The wealth of data obtained this way has transformed the theory of second messenger compartmentation into a widely accepted paradigm. It is also becoming apparent that microdomains might be the key to development of more specific car- diovascular therapeutics which could potentially lead to a breakthrough in heart failure therapy and long desired improvement of patients’ survival and care. This volume covers recent findings in the research area of second messenger microdomains with the focus on the cardiovascular system and disease, presented by the renowned leaders in the field. The first part covers cyclic nucleotide micro- domains and includes chapters on cAMP and cGMP microdomains. The second part is dedicated to calcium microdomains. v vi Preface We are grateful to all authors who provided outstanding chapters for this book. The book illustrates the work done in the field over the last decades and gives a good account of how this research has significantly advanced our understanding of the role of second messenger microdomains in cardiovascular physiology and patho- physiology. With this knowledge it is now our common interest and goal to carry these exciting insights over translational paths to new therapeutic applications. Hamburg, Germany Viacheslav Nikolaev Oxford, UK Manuela Zaccolo 2017 Contents Part I Cyclic Nucleotide Microdomains 1 Receptor-Cyclic Nucleotide Microdomains in the Heart . . . . . . . . . . . . 3 Nadja I. Bork and Viacheslav O. Nikolaev 2 Membrane Microdomains and cAMP Compartmentation in Cardiac Myocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Shailesh R. Agarwal, Rennolds S. Ostrom, and Robert D. Harvey 3 Function to Failure: Compartmentalization of Cardiomyocyte Signaling by A-Kinase- Anchoring Proteins . . . . . . 37 John M. Redden, Kimberly L. Dodge-Kafka, and Michael S. Kapiloff 4 P harmacological Approaches for Delineating Functions of AKAP- Based Signalling Complexes and Finding Therapeutic Targets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Katharina Schrade and Enno Klussmann 5 C hatting Second Messengers: PIP3 and cAMP . . . . . . . . . . . . . . . . . . . 85 Alessandra Ghigo, Flora Pirozzi, Mingchuan Li, and Emilio Hirsch 6 C yclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97 Ibrahim Bedioune, Pierre Bobin, Jérôme Leroy, Rodolphe Fischmeister, and Grégoire Vandecasteele 7 c AMP Compartmentalisation and Hypertrophy of the Heart: ‘Good’ Pools of cAMP and ‘Bad’ Pools of cAMP Coexist in the Same Cardiac Myocyte . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 Anna Zoccarato and Manuela Zaccolo 8 S ubcellular Targeting of PDE4 in Cardiac Myocytes and Generation of Signaling Compartments . . . . . . . . . . . . . . . . . . . . 143 Marco Conti 9 Cardiac cAMP Microdomains and Their Modulation Using Disruptor Peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Lauren Wills, Bracy A. Fertig, and George S. Baillie vii viii Contents 10 Computational Modeling of Cyclic Nucleotide Signaling Mechanisms in Cardiac Myocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 Claire Y. Zhao 11 Signalling Microdomains: The Beta-3 Adrenergic Receptor/NOS Signalosome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 J. Hammond and J.-L. Balligand 12 Compartmentation of Natriuretic Peptide Signalling in Cardiac Myocytes: Effects on Cardiac Contractility and Hypertrophy . . . . . . 245 Lise Román Moltzau, Silja Meier, Kjetil Wessel Andressen, and Finn Olav Levy 13 Cyclic GMP/Protein Kinase Localized Signaling and Disease Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273 Brian Leei Lin, David A. Kass, and Dong I. Lee Part II Calcium Microdomains 14 Distribution and Regulation of L-Type Ca2+ Channels in Cardiomyocyte Microdomains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293 Alexey V. Glukhov, Anamika Bhargava, and Julia Gorelik 15 The Role of Local Ca2+ Release for Ca2+ Alternans and SR-Ca2+ Leak . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321 Karin P. Hammer and Lars S. Maier 16 The Control of Sub-plasma Membrane Calcium Signalling by the Plasma Membrane Calcium ATPase Pump PMCA4 . . . . . . . . 341 Nicholas Stafford, Ludwig Neyses, and Delvac Oceandy 17 Calcium Microdomains in Cardiac Cells . . . . . . . . . . . . . . . . . . . . . . . 361 A.M. Gómez, T.R.R. Mesquita, J.J. Mercadier, J.L. Álvarez, and J.P. Benitah Part I Cyclic Nucleotide Microdomains
The list of books you might like
